Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas

Shreya Mehta\textsuperscript{1,2}, Nazim Bhimani\textsuperscript{3}, Anthony J. Gill\textsuperscript{1,2,4,5,6}, Jaswinder S. Samra\textsuperscript{1,3,5}, Sumit Sahni\textsuperscript{1,2,5*} and Anubhav Mittal\textsuperscript{1,3,5*}†

\textsuperscript{1} Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia, \textsuperscript{2} Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, Australia, \textsuperscript{3} Upper Gastro Intestinal (GI) Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, Sydney, NSW, Australia, \textsuperscript{4} Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, NSW, Australia, \textsuperscript{5} Australian Pancreatic Centre, Sydney, NSW, Australia, \textsuperscript{6} NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, NSW, Australia

Keywords: pancreatic ductal adenocarcinoma, diagnostic biomarkers, prognostic biomarkers, S100A4, Ca-125 and Ca 19-9, survival analysis

A Corrigendum on

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas

by Mehta S., Bhimani N., Gill A.J., Samra J.S., Sahni S. and Mittal A. (2021) Front. Oncol., 11: 708963
doi: 10.3389/fonc.2021.708963

In the original article, there was a mistake in Figures 2, 3, Supplementary Figure 1 and Table 1. There was an error in the survival data for some patients which has slightly modified curves. The corrected Figures 2, 3, Supplementary Figure 1 and Table 1 appears below.

In the original article, there was an error. The stated median survival and p value of survival analysis were incorrect. A correction has been made to Results, Survival Analysis Based on Serum Biomarker Levels paragraph 1 and 2:

"Survival correlation with abnormal serum biomarker levels were determined using Kaplan Meier curves. Abnormal serum levels of S100A4 (median survival (m.s.): 28.92 vs 23.29 months; Figure 2), Ca-125 (m.s.: 26.15 vs 22.18 months; Figure 2) and Ca19-9 (m.s.: 28.92 vs 23.49 months; Figure 2) led to reduction in the median overall survival time. In contrast, abnormal serum levels of S100A2 resulted in increased median survival time (m.s.: 23.72 vs 26.35 months; Figure 2). However, none of the biomarkers individually corresponded with overall survival. The panel of S100A4, Ca-125 and Ca 19-9 was further analysed to determine its ability to stratify patients based on their overall survival. Initially, patients were divided into four groups: (1) none of the biomarkers with abnormal levels (n = 6); (2) one biomarker with abnormal levels (n = 31); (3) two biomarkers with abnormal levels (n = 56); (4) three biomarkers with abnormal levels (n = 27). Multiple comparison Kaplan Meier curve analysis did not achieve statistical significance (p = 0.121; Supplementary Figure 1), potentially due to very small number of patients in some categories. The combination of first two and last two categories was able to stratify patients based on their overall survival (Figure 3). The patients with abnormal levels of one or less of the biomarker (n = 37) had significantly improved survival outcomes, compared to those with abnormal levels of two or more biomarkers (n = 83; m.s.: 36.76 vs 20.02 months, p = 0.018; Figure 3). Patient distribution based on tumour characteristics..."
was also analysed (Supplementary Table 4), which showed uniform distribution in both biomarker groups.

In the original article, there was an error. The stated median survival was incorrect. A correction has been made to Discussion, paragraph 1:

"The study demonstrates that of the select group of biomarkers included in this study, a panel of four (S100A4, S100A2, Ca-125 and Ca 19-9) have superior diagnostic potential compared to the current biomarker used in clinical practice, Ca 19-9 alone. Additionally, the abnormal expression of two or more biomarkers correlated with worse survival (median survival: 36.76 vs 20.02 months; p < 0.05). The utility of this biomarker panel in the accurate diagnosis of PDAC and implications of biomarker expression on prognosis..."
may assist with personalization of treatment and improved survival outcomes”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.774861/full#supplementary-material

### TABLE 1 | Patient and tumour characteristics and correlation with survival status.

| Characteristic         | Total n (%) | HR   | 95% CI | p-value |
|------------------------|-------------|------|--------|---------|
| Age                    |             |      |        |         |
| <70 years              | 72 (60.0)   |      |        | 0.237   |
| ≥70 years              | 48 (40.0)   | 1.27 | 0.85-1.90 | 0.706   |
| Gender                 |             |      |        |         |
| Male                   | 61 (50.8)   |      |        |         |
| Female                 | 59 (49.2)   |      |        |         |
| Tumour size            |             |      |        |         |
| <35mm                  | 55 (45.8)   |      |        | 0.009   |
| ≥35mm                  | 65 (54.2)   | 1.70 | 1.14-2.55 |         |
| T Stage                |             |      |        |         |
| T1 & T2                | 9 (7.5)     |      |        | <0.001  |
| T3 & T4                | 111 (92.5)  |      |        |         |
| Node Positive          |             |      |        |         |
| No                     | 26 (21.7)   |      |        | 0.001   |
| Yes                    | 94 (78.3)   | 2.68 | 1.51-4.76 |         |
| Vascular Invasion      |             |      |        |         |
| No                     | 46 (38.3)   |      |        | 0.024   |
| Yes                    | 74 (61.7)   | 2.49 | 1.61-3.87 |         |
| Perineural Invasion    |             |      |        |         |
| No                     | 38 (31.7)   |      |        | 0.021   |
| Yes                    | 82 (68.3)   | 1.66 | 1.07-2.58 |         |
| Grade                  |             |      |        |         |
| 0 or 1                 | 84 (70.0)   |      |        | 0.873   |
| 2 or 3                 | 36 (30.0)   | 1.65 | 1.08-2.54 |         |
| Blood loss             |             |      |        |         |
| <450mL                 | 52 (43.3)   |      |        |         |
| ≥450mL                 | 68 (56.7)   | 1.03 | 0.69-1.54 | 0.347   |
| Length of stay         |             |      |        |         |
| <12 days               | 45 (37.5)   |      |        |         |
| ≥12 days               | 75 (62.5)   | 0.82 | 0.54-1.24 | 0.002   |
| Margin Status          |             |      |        |         |
| R0                     | 49 (40.8)   |      |        |         |
| R1                     | 71 (59.2)   | 1.69 | 1.25-2.85 |         |